Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05499702 · ClinicalTrials.gov registry record · Phase 2
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
A Phase 2 study of Type2diabetes, sponsored by Adrian Vella.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05499702 is a Phase 2 study of Type2diabetes that is actively recruiting participants, run by Adrian Vella. The registered enrollment target is 20 participants, below the 493-participant average among 19 other Type2diabetes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05499702, a Phase 2 study of Type2diabetes, is actively recruiting participants, sponsored by Adrian Vella.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.
Conditions Studied
Interventions
- BEHAVIORAL Caloric Restriction
- DRUG Hyperglycemic clamp
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-12-15 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05499702
The ClinicalTrials.gov registry entry for NCT05499702 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 493-participant average among 19 other Type2diabetes trials with a reported enrollment target (96% lower). The listed sponsor is Adrian Vella, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type2diabetes appearing as the primary indexed condition, and to 2 interventions - of which Caloric Restriction is the first listed.
NCT05499702 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05499702 about?
NCT05499702 is a clinical study titled "The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction". Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepat...
What is the current status of trial NCT05499702?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-12-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05499702 study?
This clinical trial studies the following conditions: Type2diabetes.
What interventions are being tested in trial NCT05499702?
The interventions under investigation include: Caloric Restriction (BEHAVIORAL), Hyperglycemic clamp (DRUG).
Who is sponsoring clinical trial NCT05499702?
This trial is sponsored by Adrian Vella, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05499702 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type2diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAD Augmentation in Diabetes Kidney Disease
RECRUITING · Phase 2
-
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · NA
-
Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching
RECRUITING · NA
-
Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment
RECRUITING · NA
-
Type 2 Diabetes and Blood Brain Barrier Improvement
RECRUITING · Early Phase 1
-
Ketones, SGLT2, HFrEF
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.